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ABSTRACT
Objectives The aim of this study was to conduct a rapid 
systematic review and meta- analysis of estimates of the 
incubation period of COVID-19.
Design Rapid systematic review and meta- analysis of 
observational research.
Setting International studies on incubation period of 
COVID-19.
Participants Searches were carried out in PubMed, 
Google Scholar, Embase, Cochrane Library as well as 
the preprint servers MedRxiv and BioRxiv. Studies were 
selected for meta- analysis if they reported either the 
parameters and CIs of the distributions fit to the data, 
or sufficient information to facilitate calculation of those 
values. After initial eligibility screening, 24 studies were 
selected for initial review, nine of these were shortlisted for 
meta- analysis. Final estimates are from meta- analysis of 
eight studies.
Primary outcome measures Parameters of a lognormal 
distribution of incubation periods.
Results The incubation period distribution may be 
modelled with a lognormal distribution with pooled mu 
and sigma parameters (95% CIs) of 1.63 (95% CI 1.51 to 
1.75) and 0.50 (95% CI 0.46 to 0.55), respectively. The 
corresponding mean (95% CIs) was 5.8 (95% CI 5.0 to 6.7) 
days. It should be noted that uncertainty increases towards 
the tail of the distribution: the pooled parameter estimates 
(95% CIs) resulted in a median incubation period of 5.1 
(95% CI 4.5 to 5.8) days, whereas the 95th percentile was 
11.7 (95% CI 9.7 to 14.2) days.
Conclusions The choice of which parameter values 
are adopted will depend on how the information is used, 
the associated risks and the perceived consequences of 
decisions to be taken. These recommendations will need 
to be revisited once further relevant information becomes 
available. Accordingly, we present an R Shiny app that 
facilitates updating these estimates as new data become 
available.
INTRODUCTION
Reliable estimates of the incubation period 
are important for decision- making around 
the control of infectious diseases in human 
populations. Knowledge of the incuba-
tion period can be used directly to inform 
decision- making around infectious disease 
control. For example, the maximum incu-
bation period can be used to inform the 
duration of quarantine, or active monitoring 
periods of people who have been at high 
risk of exposure. Estimates of the duration 
of the incubation period, coupled with esti-
mates of the latent period, serial interval or 
generation times, may help infer the dura-
tion of the presymptomatic infectious period, 
which is important in understanding both 
the transmission of infection and opportu-
nities for control.1 Finally, decision- making 
in the midst of a pandemic often relies on 
predicted events, such as daily number of new 
infections, from mathematical models. Such 
models depend on key input parameters 
relevant to the transmission of the specific 
infectious disease. It is important that input 
parameters into such models are as robust 
as possible. Given that some models fit data 
to many parameters, only some of which are 
specifically of interest but all of which are 
interdependent, output estimates may be 
compared with the robust estimates as part of 
the validation of the model.
Earlier work has shown that for models of 
respiratory infections, statements regarding 
Strengths and limitations of this study
 ► This study provides a pooled estimate of the dis-
tribution of incubation periods which may be used 
in subsequent modelling studies or to inform 
decision- making.
 ► Several studies used data that were publicly avail-
able, therefore there is potential that some of the 
data may be used for more than one study.
 ► This estimate will need to be revisited as subsequent 
data become available. Accordingly, we present an R 
Shiny app to allow the meta- analysis to be updated 
with new estimates.
by copyright.
 o
n
 Septem
ber 16, 2020 at University of Nottingham
. Protected
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2020-039652 on 16 August 2020. Downloaded from 
2 McAloon C, et al. BMJ Open 2020;10:e039652. doi:10.1136/bmjopen-2020-039652
Open access 
incubation periods are often poorly referenced, inconsis-
tent or based on limited data.2 To date, many COVID-19 
models have used input values from a single study. The 
decision on which study to use may vary from model to 
model. Recently, a systematic review of the epidemiolog-
ical characteristics of COVID-19 reported that estimates 
of the central tendency of the incubation period ranged 
from 4 to 6 days.3 However, to the authors’ knowledge, no 
studies have yet sought to estimate the incubation period 
through a meta- analysis of data available to date. Further-
more, it is important to note that incubation periods are 
expected to vary across individuals within the population. 
For this reason, it is critically important to understand 
the variation in incubation periods (ie, the distribution) 
within the population. However, a single measure of 
central tendency (ie, mean or median) cannot adequately 
represent this variation.4 To address this, studies often fit 
mathematical distributions to incubation period data.
We hypothesised that a pooled estimate of the distri-
bution of incubation periods could be obtained through 
a meta- analysis of data published to date. Therefore, the 
aim of this study was to conduct a rapid systematic review 
and meta- analysis of estimates of the incubation periods 
of COVID-19, defined as the period of time (in days) from 
virus exposure to the onset of symptoms. Specifically, we 
aimed to find a pooled estimate for the parameters of 
an appropriate distribution that could be subsequently 
used as an input in modelling studies and that might help 
quantify uncertainty around the key percentiles of the 
distribution as an aid to decision- making.
MATERIALS AND METHODS
For the purpose of this study we followed the Meta- 
analysis of Observational Studies in Epidemiology guide-
lines.5 The outcome was defined as the time in days from 
the point of exposure (in this case, infection) to the onset 
of clinical signs; all observational studies were included 
in the analysis. Finally, the population was confirmed 
infected individuals, where an exposure time could be 
ascertained with some degree of certainty and precision.
Patient and public involvement
It was not appropriate or possible to involve patients or 
the public in the design, or conduct, or reporting, or 
dissemination plans of our research.
Search methodology, initial screening and categorisation
A survey of the literature between 1 December 2019 
and 8 April 2020 for all countries was implemented 
using the following search strategy. Publications on the 
electronic databases PubMed, Google Scholar, Embase, 
Cochrane Library as well as the preprint servers MedRxiv 
and BioRxiv were searched with the following keywords: 
‘Novel coronavirus’ OR ‘SARS- CoV-2’ OR ‘2019- nCoV’ 
OR ‘COVID-19’ AND ‘incubation period’ OR ‘incuba-
tion’ (online supplementary table S1). The dynamic 
curated PubMed database ‘LitCovid’ was also monitored, 
in addition to national and international government 
reports. No restrictions on language or publication status 
were imposed so long as an English abstract was available. 
Articles were evaluated for data relating to the aim of this 
review, and all relevant publications were considered for 
possible inclusion. Bibliographies within these publica-
tions were also searched for additional resources. The 
initial searches were carried out by three of the investiga-
tors (ÁC, KH, FB). Authors of studies were contacted only 
to clarify reporting queries.
Initial study appraisal and selection for meta-analysis
Results of searches were screened in two stages. First, 
titles and abstracts were screened, and only relevant arti-
cles retained. Studies were removed if they dealt with 
specific cohorts of cases that did not reflect the overall 
population. Next, articles were read in detail, studies 
were selected for meta- analysis if they reported either the 
parameters and CIs of the distributions fit to the data, 
or sufficient information to facilitate calculation of those 
values. Specifically, this included studies that reported: 
the point estimate and CIs or SEs of each parameter; 
the mean and SD on the original (non- transformed) 
scale with CIs; the mean and one or more percentiles of 
the distribution (with CIs); or two or more percentiles 
of the distribution (with CIs). Studies were excluded if 
they described the distribution (eg, with mean, median, 
percentile) but did not report any uncertainty around 
that figure. The selection of studies to include in the 
meta- analysis was conducted by the primary author (CM).
Quality assessment of shortlisted studies
Once studies were shortlisted, two authors (CM, SJM) 
independently conducted appraisals of study quality. To 
the authors’ knowledge, no quality assessment tools are 
available to appraise studies reporting the incubation 
period of infectious disease. We used the Newcastle- 
Ottawa Scale for assessing the quality of non- randomised 
studies in meta- analyses6 as a basis and modified it 
according to important quality and reporting indicators 
for studies investigating incubation period. In partic-
ular, fields were added which assessed the accuracy and 
precision with which the exposure windows were defined. 
Fields relevant to non- exposed cohorts were removed. 
Finally, we replaced the ‘star’ system with a lettered cate-
gorical system for each item on the scale. The modified 
scale is provided as online supplementary material. After 
both authors had appraised the studies, the results were 
compared and differences in scores resolved through 
discussion until a consensus was reached.
Data extraction
On initial appraisal, it was apparent that the majority of 
studies fitted a lognormal distribution to the data. Earlier 
work has shown that this distribution is appropriate for 
many acute infectious diseases.2 7 Therefore, the study 
proceeded as the meta- analysis (pooled estimate) of the 
parameters of this distribution.
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A variable (X) has a lognormal distribution when the 
log- transformed values follow a normal distribution with 
mean, mu, and variance, sigma2, that is:
 ln(X) ∼ N(mu, sigma2) 
Methods exist for the meta- analysis of studies that 
combine a mix of log- transformed and non- transformed 
data.8 In this case we opted to transform data, where 
possible to the log- transformed scale, and obtain a pooled 
estimate of both mu and sigma.
Calculation of distribution parameters from each study
Where the values for each parameter (mu and sigma) were 
available from the studies, along with corresponding CIs/
SEs, these were extracted as reported. In the remaining 
studies, the values were calculated where possible from 
the information presented.
Calculation of mu and sigma from studies reporting the mean and 
SD of the lognormal distribution on the original scale
The mu and sigma parameters of the original lognormal 
distribution were calculated as:
 mu = ln
(
m
)− sigma22  
 
sigma =
√
ln
(
υ
m2
+ 1
)
 
where v=variance (=SD2), and m=the mean of the distri-
bution on the original (ie, non- log transformed) scale.
Similarly, upper and lower CIs of mu and sigma were 
found by substituting the upper and lower bounds of 
the mean or SD (from the original scale) into the equa-
tion above, one at a time, while holding the value for the 
other parameter constant (as the point estimate for that 
parameter).
Calculation of mu and sigma from studies reporting mean and 
percentiles on the original scale
Where studies reported the results as the mean and 95th 
percentile on the original scale, the ‘lognorm’ package 
in R was used to calculate the original values of mu and 
sigma and corresponding SEs or CIs.9
Calculation of variance of mu and sigma
For studies reporting CIs, the SE was calculated as (upper 
bound – lower bound)/(2×1.96). Finally, for studies 
reporting the parameters relative to a referent value, the 
SE was calculated as:
 
√
SE12 + SE22  
where SE1 and SE2 are the SEs of the estimate of the 
referent category and coefficient, respectively.
Meta-analysis
A random effects meta- analysis was conducted in RStudio 
V.1.2.5033,10 using the ‘metafor’ package,11 of the mu and 
sigma parameters of the lognormal distribution, speci-
fying the point estimate and the SE using ‘yi’ (ie, the point 
estimate) and ‘sei’ (ie, the SE) arguments. Forest plots 
were produced using the same package. Quantitative 
estimates of bias were obtained using the Egger’s test and 
funnel plots. Heterogeneity was quantified using the I2 
statistic and investigated by conducting subgroup anal-
yses of the data set.
Calculation of the SEM and SD on the original scale from pooled 
estimates of mu and sigma
The mean and SD of the pooled estimate were converted 
to the original (ie, non- log transformed) scale as:
 Mean = e
(
mu+ sigma
2
2
)
 
 SD =
√
e
(
2×mu+sigma2) × e(sigma2−1)  
The upper and lower CIs were found by substituting, 
one at a time, the upper and lower bounds for mu and 
sigma and recalculating the subsequent figures for mean 
and SD.
The resulting distribution was plotted using the 
‘ggplot2’ package in R.12 In addition, the distributions for 
studies that did not fit a lognormal distribution, but that 
reported the parameters of an alternative distribution 
fitted were also plotted alongside the pooled lognormal 
distribution.
Finally, an R Shiny app was created which allows the 
meta- analysis estimates to be updated as new data become 
available.
RESULTS
After initial search and selection of relevant papers 
and removing duplicates, 24 studies were available for 
appraisal.
 ► Two papers were removed as they dealt with specific 
cohorts of cases—young adults13 and children.14
 ► One study was removed since only the abstract was in 
English and there was not enough detail to extract the 
relevant results.15
 ► Several papers were removed since they contained 
insufficient data or method description to facilitate 
their inclusion:
 – One study was removed since there was not enough 
detail in the paper to determine whether new pa-
rameters were being estimated or whether the 
parameters quoted were input values for their 
model.16
 – Seven papers were removed since the data were 
largely descriptive, with no CIs reported.17–23
 – One study was removed because the error terms 
associated with the mean, median and percentiles 
were not reported and there was not enough infor-
mation presented to recover the parameters of the 
lognormal distribution.24
 – One study was removed25 since a novel statistical 
approach was employed that likely resulted in a 
significantly higher incubation period estimate to 
other studies.
Of the shortlisted studies (n=11), six reported 
lognormal distributions as best fitting the data.26–31 Of 
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the remaining four, one reported that several distri-
butions were trialled but it was not clear which distri-
bution was used for the final estimates.32 However, 
these authors provided raw data which we used to fit 
the parameters of the lognormal distribution using 
the ‘rriskDistributions’ package.33 The remaining four 
studies reported that either Weibull or gamma distri-
butions fitted the data better. Of these, two study also 
presented the results of a lognormal distribution fit to 
the data,34 35 facilitating their inclusion in the subse-
quent analysis. One of these studies35 reported the incu-
bation period for two distinct cohorts: travellers and 
non- travellers to Hubei. The estimates for the cohorts 
were significantly different. The author suggested that 
this difference was possibly explained by multiple expo-
sures in the traveller cohort. Therefore, we chose to 
only use the estimates reported for the non- traveller 
cohort in our analysis.
The final two studies reporting a Weibull36 and a gamma 
distribution37 were removed from further analysis at this 
stage, however, those distributions were plotted over the 
final distribution to evaluate the impact of removing those 
estimates. The characteristics of the final studies as well as 
the final mu and sigma values used for meta- analysis are 
shown in table 1.
Quality assessment (online supplementary table S2) 
indicated that few studies precisely outlined the exposure 
windows and symptom- onset windows that were used in 
their studies. Several studies reported that they conducted 
analysis on a small cohort of well- characterised cases. 
Likely this only includes individuals with short (1 day) 
exposure and symptom- onset windows. However, this was 
not clearly reported in several studies.
The initial pooled estimate of mu from this data set 
(ie, data set 1, n=8 studies) was 1.66 (1.55, 1.76) and 
the pooled estimate of sigma was 0.48 (0.42, 0.54). The 
I2 values were 75% and 56% for mu and sigma, respec-
tively. Egger’s tests for mu and sigma were not statistically 
significant; p=0.31 and p=0.20 for mu and sigma, respec-
tively. However, evaluation of the funnel plots (online 
supplementary figures S1 and S2) suggests the potential 
for bias associated with one of the studies included in the 
analysis.30 Evaluation of the meta- analyses results for mu 
demonstrated that two studies were responsible for much 
of the heterogeneity in the analysis of this value. In partic-
ular, the values reported by Ma et al30 and Backer et al34 
were higher than the estimates from other studies. Both 
studies were further evaluated to determine whether 
these differences may have been due to methodological 
differences. The Backer et al34 study was subsequently 
excluded since it appeared that the exposure window was 
somewhat imprecisely defined which would have biased 
this estimate upwards. Conversely, the study reported by 
Ma et al30 used only patients where the exposure window 
was 3 days or less, with the majority of those of a 1 day 
duration. The meta- analysis was repeated with the Backer 
et al34 study removed (ie, data set 2, n=7 studies). The 
resulting pooled estimates were 1.63 (1.51, 1.75) and 
0.50 (0.46, 0.55), while the I2 values were 75% and 24% 
for mu and sigma, respectively. Figures 1 and 2 show the 
resulting forest plots for the meta- analyses of mu and 
sigma, respectively, from data set 2 (n=8), that is, the nine 
studies from which the parameters were extracted, minus 
the Backer et al34 estimate.
Figure 3 shows the resulting density plot of the pooled 
distribution. Figure 4 shows the cumulative density 
function plot of the same (pooled distribution). In this 
instance, all possible combinations of distributions across 
the 95% CIs of the estimates of each of the mu and sigma 
values are plotted on the same graph. Table 2 shows 
the percentiles and corresponding CIs of the pooled 
lognormal distribution.
Figure 5 shows the cumulative density function plots 
of the pooled lognormal distribution along with the esti-
mates from the original studies. Finally, figure 6 shows 
the probability density function of the pooled lognormal 
distribution, plotted alongside the two studies that could 
not be included in the final meta- analysis due to the fact 
that they fit alternative distributions to the data.
DISCUSSION
For the purpose of this study we defined incubation 
period as the time in days from the point of COVID-19 
exposure to the onset of symptoms. Online supplemen-
tary figure S3 shows a schematic of this time period with 
respect to other key parameters influencing COVID-19 
transmission. Studies to determine incubation period are 
likely most precise during the early phase of the outbreak, 
before the pathogen is widespread.26 During this early 
phase, exposure windows can be determined with some 
confidence. Most studies achieved this by conducting the 
analysis based on travellers from an epicentre of infection 
(Wuhan) to another country/region that was free from 
infection at that time point or in the very early stages of 
the outbreak.
Issues with ascertaining incubation period in primary studies
By definition, the required case data for the determina-
tion of individual incubation periods need to include 
both exposure (window) and onset of symptoms. Precisely 
estimating these events can be difficult. Symptom onset 
is based on case recall, whereas exposure is determined 
either from: movement history, thereby providing a 
window prior to movement of potential exposure, or a 
known window of exposure (from earliest to latest) to 
a confirmed case (close contact). However, exposure 
and/or symptom onset are rarely observed exactly. The 
methods used to deal with this include restricting the 
analysis to data from patients where the exposure window 
could be narrowed to a short window (eg, <3 days); taking 
a median point from the exposure window to determine 
the exposure time point. Alternatively, Linton et al29 
included left exposure dates as parameters to be fitted 
in the model. However, several studies did not report the 
duration of the exposure and symptom- onset windows 
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for cases used in their analyses. In many cases, these were 
described as ‘well characterized’ cohorts of cases and 
likely only included 1 day windows, however, we recom-
mend that future studies explicitly report if this is the 
case.
Investigating heterogeneity
After the initial meta- analysis we decided to remove the 
Backer et al34 study from the pooled estimate. The estimates 
from that study were found to be shifted considerably to 
the right compared with other estimates. Examination of 
that study identified that many of the patients had long 
exposure windows which would be expected to bias the 
estimate upwards. Interestingly, that study conducted 
an additional subset analysis of patients whose exposure 
windows were well defined and for these data, the mean 
incubation period dropped from 6.4 to 4.5 days. However, 
it is interesting to note that Ma et al30 restricted their anal-
ysis to patients with a 3- day exposure window and still 
found a mean incubation period of 7.4 days. Since this 
study had the largest sample size (n=587), it has a signifi-
cant impact on the estimation of the lognormal parame-
ters. Repeating the meta- analysis with both the Backer et 
al34 and Ma et al30 studies removed results in values of 1.58 
(1.51, 1.64) and 0.47 (0.42, 0.53), respectively. With both 
of these studies removed the I2 values drop to 0% for both 
parameters. The corresponding mean and median are 
5.48 and 4.85 days, respectively. Interestingly, removing 
this study also increases the precision of the estimate of 
the value for mu.
Weaknesses and limitations
One of the weaknesses of our approach is that we 
extracted and analysed the parameters of the lognormal 
distribution independently. However, in reality the 
parameters and the initial distribution that they are fitted 
to are linked. We were unable to include two studies that 
did not fit lognormal distributions to the data. However, 
figure 6 demonstrates that the impact of removing these 
studies is likely to be small since they are similar to the 
pooled estimate, with one falling to the left of the pooled 
estimate, and the other falling to the right. Ideally, we 
Figure 1 Forest plot of the random effects (RE) meta- 
analysis of mu parameter of the lognormal distribution of 
incubation period.
Figure 2 Forest plot of the random effects (RE) meta- 
analysis of sigma parameter of the lognormal distribution.
Figure 3 Probability density function of the pooled 
lognormal distribution of reported incubation period with 
mu=1.63 and sigma=0.50.
Figure 4 Cumulative distribution function of pooled 
lognormal distribution. Each possible combination of values 
between the 95% CIs of mu and sigma is plotted as single 
black lines.
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would have fit distributions to the raw data available from 
each of the studies, in a way that facilitated the distribu-
tions to vary across studies. Such an approach was taken 
by Lessler et al2 in reviewing acute respiratory viral infec-
tions. However, the raw data were not available in all 
cases for the studies that we examined. Another limita-
tion is that many of the papers included in this study used 
publicly available data to estimate incubation period. 
Therefore, there is a reasonable chance that several of 
the analyses have reused at least some of the same data. In 
these cases, the studies would not be independent of each 
other. Finally, since this study was conducted as a rapid 
review, we did not seek raw data from studies that were 
excluded, nor did we seek to translate studies that were 
not published in English. However, we provide an R Shiny 
app (https:// mcaloon- ucd. shinyapps. io/ shiny2/) which 
facilitates testing the sensitivity of our pooled estimate to 
the inclusion of a single new study. This analysis demon-
strates that our pooled estimate is largely unaffected by 
new estimates. Trialling the inclusion of a new study that 
reports considerably different estimates of the incuba-
tion period has very little impact on the overall pooled 
estimate.
Comparison with values used in epidemiological modelling 
studies
It is worth noting that the parameter values from our 
meta- analysis are somewhat higher than previously used 
in modelling studies. For example, Ferguson et al38 used 
a mean of 5.1 days for incubation period, citing two 
previous studies.29 37 Mean incubation period from our 
meta- analysis was 5.8. Tuite et al,39 on the other hand, used 
an incubation period of 5.0 days citing the study by Lauer 
et al.27 This figure (5.0 days) was the median incubation 
period reported from that study,27 which is much closer 
to the median estimate of 5.1 days from our meta- analysis.
External validity
It is reasonable to assume that the incubation period 
estimated here should be relatively generalisable across 
different populations: unlike parameters such as serial 
interval, for example, incubation period depends only 
on the interaction between the virus and the host, which 
is expected to be similar across populations, and not on 
behavioural factors such as frequency of contacts which 
might be expected to vary across different countries. 
However, there is potential for a number of biases in these 
data which may impact on their external validity: in order 
to accurately estimate incubation period, it is possible 
that well- characterised cases may be preferentially chosen 
Table 2 Percentiles of the pooled lognormal distribution 
after simulating all possible combinations of mu and 
sigma within the 95% CIs of the pooled estimates of both 
parameters
Percentile
Median 
(days) Min Max
Difference 
(max − min)
2.5th 1.92 1.54 2.38 0.84
5th 2.24 1.83 2.75 0.92
10th 2.69 2.24 3.23 0.99
25th 3.64 3.12 4.25 1.13
50th 5.10 4.53 5.75 1.22
75th 7.15 6.13 8.34 2.21
90th 9.69 8.06 11.60 3.54
95th 11.60 9.49 14.20 4.71
97.5th 13.60 10.9 16.90 6.00
The median days for each percentile are shown along with the 
minimum and maximum values for that percentile.
Figure 5 Cumulative distribution function of pooled 
lognormal distribution for incubation period and original input 
studies.
Figure 6 Probability density function of pooled lognormal 
distribution for incubation period and studies (n=2) not 
included in the meta- analysis because of the distribution 
used.
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to reduce the impact of prolonged exposure windows. 
It is possible that such cases could be biased towards 
more severe cases. In that case, the estimate for incu-
bation period could be biased downwards, since it is 
possible that the incubation period could be shorter in 
more severely affected individuals. Furthermore, these 
well- characterised cases (ie, those cases where exposure 
windows and dates of symptom onset are determined with 
a high degree of certainty) may not have been representa-
tive of all cases (often male, often younger34), highlighting 
the need for information on incubation period from 
older people, people with comorbidities, from women 
and those with mild symptoms. These findings are mostly 
based on studies from Chinese patients. While the incu-
bation period for a given set of circumstances should be 
similar across different populations, there may be factors 
that might impact on incubation period, such as infec-
tious dose, for example, that might vary between popu-
lations (and possibly within populations over the course 
of the outbreak), meaning that the resulting distribu-
tion may vary for different populations, or potentially at 
different stages of the outbreak. Incubation periods may 
also be different for people of different ages.13 Finally, a 
recent study has also suggested that patients undergoing 
surgery during the incubation period may have an accel-
erated progression to clinical signs, suggesting that those 
experiencing severe stresses during the incubation period 
may have a shorter time to the onset of clinical signs.40
CONCLUSION
Based on available evidence, we find that the incubation 
period distribution may be modelled with a lognormal 
distribution with pooled mu and sigma parameters of 
1.63 (1.51, 1.75) and 0.50 (0.45, 0.55), respectively. It 
should be noted that uncertainty increases towards the 
tail of the distribution (figure 4 and table 2). The choice 
of which parameter values are adopted will depend on 
how the information is used, the associated risks and the 
perceived consequences of decisions to be taken. The 
corresponding mean was 5.8 days and the median was 5.1 
days. These recommendations will need to be revisited 
once further relevant information becomes available. 
Accordingly, we present an R Shiny app which facilitates 
users to update these estimates as new data become avail-
able, https:// mcaloon- ucd. shinyapps. io/ shiny2/
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